Developing advanced tools for designing covalent drugs
EnzyDock-based Multistate and Multiscale Tools for Covalent Drug Design
['FUNDING_R21'] · UNIVERSITY OF TEXAS ARLINGTON · NIH-10756568
This study is working on new computer tools to help create better medicines that can more accurately target specific problems in the body, which means patients could get safer and more effective treatments with fewer side effects.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS ARLINGTON (nih funded) |
| Locations | 1 site (ARLINGTON, UNITED STATES) |
| Trial ID | NIH-10756568 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative computational tools to design covalent drugs that can effectively target biological molecules. By integrating advanced quantum mechanical and molecular mechanical methods with existing docking platforms, the project aims to improve the accuracy of predicting how these drugs interact with their targets. This approach will help address issues related to off-target effects and toxicity, making drug design safer and more effective. Patients may benefit from new medications that are more precisely designed to treat their conditions with fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who may benefit from new covalent drug therapies for their specific health conditions.
Not a fit: Patients who do not have conditions that could be treated with covalent drugs may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective covalent drugs for various medical conditions.
How similar studies have performed: Other research has shown promise in using computational methods for drug design, indicating that this approach could lead to significant advancements.
Where this research is happening
ARLINGTON, UNITED STATES
- UNIVERSITY OF TEXAS ARLINGTON — ARLINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAM, KWANGHO — UNIVERSITY OF TEXAS ARLINGTON
- Study coordinator: NAM, KWANGHO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.